PF15 是一种由 FLT3 kinase 配体与 CRBN 配体相连构成的 PROTAC,作为高选择性 FLT3-ITD 降解剂,其 DC50 值为 76.7 nM,能显著抑制 FLT3-ITD 阳性细胞增殖并下调 FLT3 和 STAT5 的磷酸化,还能抑制小鼠模型中的肿瘤生长,可用于白血病研究(粉色:FLT3 靶蛋白配体;蓝色:Cereblon 配体 (MS-O60836);黑色:连接子)。
产品编号: MS-S12055 CAS No.: 2892631-70-6 分子式: C44H49N13O6 分子量: 855.94
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

PF15 是一种由 FLT3 kinase 配体与 CRBN 配体相连构成的 PROTAC,作为高选择性 FLT3-ITD 降解剂,其 DC50 值为 76.7 nM,能显著抑制 FLT3-ITD 阳性细胞增殖并下调 FLT3 和 STAT5 的磷酸化,还能抑制小鼠模型中的肿瘤生长,可用于白血病研究(粉色:FLT3 靶蛋白配体;蓝色:Cereblon 配体 (MS-O60836);黑色:连接子)。

生物实验数据

生物活性 PF15 is a PROTAC formed by linking a FLT3 kinase ligand to a CRBN ligand, acting as a highly selective FLT3-ITD degrader with a DC50 value of 76.7 nM; it significantly inhibits the proliferation of FLT3-ITD-positive cells, downregulates the phosphorylation of FLT3 and STAT5, suppresses tumor growth in mouse models, and can be used for leukemia research (pink: FLT3 target protein ligand; blue: Cereblon ligand (MS-O60836); black: linker).
体外研究
(In Vitro)

PF15 (0-1000 nM; 72 h) shows good anti-proliferation activity in MV4-11, Molm-13 and BaF3 cells (transformed ITD, ITD-D835V, and ITD-F691L mutations).
PF15 (1, 3, 10, 30, 100, 300, 1000 nM; 6 h) obviously induces FLT3 degradation in a dose-dependent manner and (10, 30, 100, 300, 1000 nM; 6 h) dramatically inhibits the phosphorylation of FLT3 and STAT5 in BaF3-FLT3-ITD cells.
PF15 (10, 30, 100, 300, 1000 nM; 6 h) sharply downregulates the phosphorylation of FLT3 and STAT5 at 100 nM in both BaF3-FLT3-ITD-D835V and BaF3-FLT3-ITD-F691L cells.
PF15 (100 nM; 1, 3, 6, 12, 24 h) induces FLT3 degradation in a time-dependent manner from 1 h to 24 h.
PF15 (15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000 nM; 24 h) induces FLT3 degradation with a DC50 of 76.7 nM.

Cell Proliferation Assay

Cell Line: MV4-11, Molm-13, BaF3 cells (transformed ITD, ITD-D835V, and ITD-F691L mutations)
Concentration: 0-1000 nM
Incubation Time: 72 h
Result: Exhibited anti-proliferation activity with IC50s of 4.83 nM (MV4-11), 4.01 nM (Molm-13) and 7.85, 120.1, 116.6 nM (for transformed BaF3 cells harboring ITD, ITD-D835V, and ITD-F691L mutations respectively).

Western Blot Analysis

Cell Line: BaF3-FLT3-ITD, BaF3-FLT3-ITD-D835V, BaF3-FLT3-ITD-F691L cells
Concentration: 1, 3, 10, 30, 100, 300, 1000 nM
Incubation Time: 6 h
Result: Induced FLT3 degradation when at 3 nM and in a dose-dependent manner in BaF3-FLT3-ITD cells.
Dramatically inhibited the phosphorylation of FLT3 and STAT5 when concentration up to 30 nM in BaF3-FLT3-ITD cells, and at 100 nM in both BaF3-FLT3-ITD-D835V and BaF3-FLT3-ITD-F691L cells.

Western Blot Analysis

Cell Line: BaF3-FLT3-ITD cells
Concentration: 100 nM
Incubation Time: 1, 3, 6, 12, 24 h
Result: Significantly induced FLT3 degradation in a time-dependent manner, and FLT3 completely degraded when at 24 h.

Western Blot Analysis

Cell Line: BaF3-FLT3-ITD cell
Concentration: 15.6, 31.2, 62.5, 125, 250, 500, 1000, 2000 nM
Incubation Time: 24 h
Result: Notably induced FLT3 degradation when at 125 nM, and DC50 was 76.7 nM.
体内研究
(In Vivo)

PF15 (10 or 20 mg/kg; i.p.; once daily for 10 days) shows good tumor growth inhibition with an inhibitory rate of 58.4% at dosage of 10 mg/kg, and when up to 20 mg/kg displays higher inhibitory rate.
PF15 (twice daily (20 mg/kg), once daily (40 mg/kg); 12 days; i.p.) prolongs the median survival up to 15 days (negative control group is 11 days) in BaF3-FLT3-ITD in situ model.

Animal Model: Female NOD/SCID mice (BaF3-FLT3-ITD xenograft model).
Dosage: 10 or 20 mg/kg
Administration: Intraperitoneal injection; once daily for 10 days.
Result: Achieved good tumor growth inhibition with an inhibitory rate of 58.4% (10 mg/kg), meanwhile, when at 20 mg/kg displayed higher inhibitory rate.
Hardly caused side effects on heart, liver, and kidney (both of the treatment groups).
Animal Model: Female BALB/c nude mice (BaF3-FLT3-ITD in situ model).
Dosage: 20, 40 mg/kg
Administration: Intraperitoneal injection; twice daily (20 mg/kg), once daily (40 mg/kg); 12 days.
Result: Prolonged the median survival from 11days to 15 days (both of the treatment groups).

化学信息

分子量 855.94
分子式 C44H49N13O6
CAS No. 2892631-70-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (116.83 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.1683 mL5.8415 mL11.6831 mL29.2077 mL
5 mM0.2337 mL1.1683 mL2.3366 mL5.8415 mL
10 mM0.1168 mL0.5842 mL1.1683 mL2.9208 mL
15 mM0.0779 mL0.3894 mL0.7789 mL1.9472 mL
20 mM0.0584 mL0.2921 mL0.5842 mL1.4604 mL
25 mM0.0467 mL0.2337 mL0.4673 mL1.1683 mL
30 mM0.0389 mL0.1947 mL0.3894 mL0.9736 mL
40 mM0.0292 mL0.1460 mL0.2921 mL0.7302 mL
50 mM0.0234 mL0.1168 mL0.2337 mL0.5842 mL
60 mM0.0195 mL0.0974 mL0.1947 mL0.4868 mL
80 mM0.0146 mL0.0730 mL0.1460 mL0.3651 mL
100 mM0.0117 mL0.0584 mL0.1168 mL0.2921 mL
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础